Literature DB >> 1577226

Soluble HLA class I antigens in sera of patients with chronic hepatitis.

K Sakaguchi1, N Koide, T Takenami, H Matsushima, H Takabatake, S Ferrone, T Tsuji.   

Abstract

Soluble HLA Class I antigens in sera (serum-HLA Class I, s-HLA Class I) of patients with chronic hepatitis (CH) were measured with an enzyme-linked double determinant immunoassay (E-DDIA). The mean titers of s-HLA Class I antigens of patients with CPH (mean +/- standard deviation, 2.22 +/- 1.60), CAH2A (2.24 +/- 1.65) or CAH2B (2.73 +/- 1.46) were significantly higher than that of normal subjects (0.36 +/- 0.27) (P less than 0.01). The titer of s-HLA Class I correlated significantly with the level of serum glutamic pyruvic transaminase (s-GPT) (r = 0.73), and weakly with serum level of beta 2-microglobulin (r = 0.43). In patients with chronic hepatitis type B (CH-B) treated with human lymphoblastoid interferon alpha (IFN-alpha), the titer of s-HLA Class I antigens increased. The increased level of s-HLA Class I antigens in the clinical course of chronic hepatitis may be caused by their release from necrotizing hepatocytes which have acquired the expression of HLA Class I antigens on the cell-surface membrane during viral infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577226     DOI: 10.1007/bf02777724

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  22 in total

1.  Immunohistochemical study of HLA class 1 antigens on the hepatocytes of patients with chronic hepatitis B.

Authors:  K Manabe; G Yamada; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1986-08

2.  HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection.

Authors:  M Pignatelli; J Waters; D Brown; A Lever; S Iwarson; Z Schaff; R Gerety; H C Thomas
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

3.  Anti-HLA-B7,B27,Bw42,Bw54,Bw55,Bw56, Bw67,Bw73 monoclonal antibodies: specificity, idiotypes, and application for a double determinant immunoassay.

Authors:  K Sakaguchi; R Ono; M Tsujisaki; P Richiardi; A Carbonara; M S Park; R Tonai; P I Terasaki; S Ferrone
Journal:  Hum Immunol       Date:  1988-03       Impact factor: 2.850

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Acute and chronic hepatitis revisited. Review by an international group.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

6.  Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin.

Authors:  P G Natali; A Bigotti; M R Nicotra; M Viora; D Manfredi; S Ferrone
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

7.  Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection.

Authors:  L Montano; G C Miescher; A H Goodall; K H Wiedmann; G Janossy; H C Thomas
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

8.  The free and the beta 2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28.

Authors:  V Quaranta; L E Walker; G Ruberto; M A Pellegrino; S Ferrone
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

9.  Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.

Authors:  K A Fleming; A McMichael; J A Morton; J Woods; J O McGee
Journal:  J Clin Pathol       Date:  1981-07       Impact factor: 3.411

10.  The small subunit of HL-A antigens is beta 2-microglobulin.

Authors:  H M Grey; R T Kubo; S M Colon; M D Poulik; P Cresswell; T Springer; M Turner; J L Strominger
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  7 in total

1.  Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.

Authors:  F Puppo; F Torre; P Contini; M Ghio; S Brenci; R Brizzolara; N Sinelli; N Campo; F Indiveri; A Picciotto
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.

Authors:  Giuseppe Murdaca; Paola Contini; Paola Cagnati; Simona Marenco; Giulia Pieri; Francesca Lantieri; Antonino Picciotto; Francesco Puppo
Journal:  Clin Exp Med       Date:  2015-11-14       Impact factor: 3.984

Review 3.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

4.  Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia.

Authors:  S Migliaresi; A Bresciani; L Ambrosone; M Spera; D Barbarulo; V Lombari; G Pirozzi; G Borgia; M L Lombardi; G Tirri; C Manzo
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

5.  Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders.

Authors:  M Hagihara; T Shimura; K Takebe; B Munkhbat; K Hosoi; T Kagawa; N Watanabe; S Matsuzaki; K Yamamoto; K Sato; K Tsuji
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

6.  Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?

Authors:  F Puppo; A Picciotto; S Brenci; G Varagona; M Scudeletti; M Ghio; V Balestra; G Celle; F Indiveri
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

7.  Neopterin and beta-2 microglobulin relations to immunity and inflammatory status in nonischemic dilated cardiomyopathy patients.

Authors:  Celina Wojciechowska; Jan Wodniecki; Romuald Wojnicz; Ewa Romuk; Wojciech Jacheć; Andrzej Tomasik; Bronisława Skrzep-Poloczek; Beata Spinczyk; Ewa Nowalany-Kozielska
Journal:  Mediators Inflamm       Date:  2014-08-18       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.